IGF-I and IGFBP-3 polymorphisms and risk of prostate cancer

Danielle M. Friedrichsen, Sarah Hawley, Jainfen Shu, Mariela Humphrey, Leah Sabacan, Lori Iwasaki, Ruth Etzioni, Elaine A. Ostrander, Janet L. Stanford

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

BACKGROUND. Insulin-like growth factor-I (IGF-I) is a potent mitogen for both normal and malignant prostate epithelial cells. The majority of circulating IGF-I is bound in a complex with IGF binding protein-3 (IGFBP-3), which in turn limits IGF-I bioavailability. Multiple studies suggest that higher IGF-I and/or lower IGFBP-3 serum levels are positively associated with prostate cancer risk. Several polymorphisms within the IGF-I and IGFBP-3 coding regions have been associated with increased serum protein levels. METHODS. To ascertain the potential relationship between serum levels and polymorphism, and prostate cancer risk, we investigated the role of two polymorphisms the IGF-I cytosine-adenosine (CA)-repeat and the IGFBP-3 Ala32Gly, and prostate cancer in a population-based, case-control, study of middle-aged men. RESULTS. We found no significant association between the IGFBP-3 Ala32Gly polymorphism and prostate cancer risk, even though the presence of at least one Gly allele did correlate with increased serum levels of IGFBP-3. For IGF-I, more controls (42%) than cases (38%) were homozygous for 19-CA-repeats (odds ratio, OR = 0.85; 95% confidence interval (CI) = 0.66-1.09). After stratifying by disease characteristics, 19-CA-repeat homozygous men displayed a decreased risk of low-grade disease (OR = 0.50; 95% CI = 0.27-0.93), but no associations were observed with more aggressive features of disease. Additionally, there was no correlation between mean serum IGF-I protein levels and IGF-I genotype in controls. CONCLUSIONS. Further evaluation of the IGF-I CA-repeat polymorphism and prostate cancer is necessary to determine if the modest risk reduction associated with the 19-CA-repeat homozygous state is observed in other study populations.

Original languageEnglish (US)
Pages (from-to)44-51
Number of pages8
JournalProstate
Volume65
Issue number1
DOIs
StatePublished - Sep 15 2005
Externally publishedYes

Fingerprint

Insulin-Like Growth Factor Binding Proteins
Insulin-Like Growth Factor Binding Protein 3
Insulin-Like Growth Factor I
Prostatic Neoplasms
Cytosine
Adenosine
Serum
Confidence Intervals
Risk Reduction Behavior
Mitogens
Population
Biological Availability
Open Reading Frames
Case-Control Studies
Blood Proteins
Prostate
Epithelial Cells
Alleles
Odds Ratio
Genotype

Keywords

  • IGF-I
  • IGFBP-3
  • Polymorphisms
  • Prostate cancer
  • Relative risk

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Friedrichsen, D. M., Hawley, S., Shu, J., Humphrey, M., Sabacan, L., Iwasaki, L., ... Stanford, J. L. (2005). IGF-I and IGFBP-3 polymorphisms and risk of prostate cancer. Prostate, 65(1), 44-51. https://doi.org/10.1002/pros.20259

IGF-I and IGFBP-3 polymorphisms and risk of prostate cancer. / Friedrichsen, Danielle M.; Hawley, Sarah; Shu, Jainfen; Humphrey, Mariela; Sabacan, Leah; Iwasaki, Lori; Etzioni, Ruth; Ostrander, Elaine A.; Stanford, Janet L.

In: Prostate, Vol. 65, No. 1, 15.09.2005, p. 44-51.

Research output: Contribution to journalArticle

Friedrichsen, DM, Hawley, S, Shu, J, Humphrey, M, Sabacan, L, Iwasaki, L, Etzioni, R, Ostrander, EA & Stanford, JL 2005, 'IGF-I and IGFBP-3 polymorphisms and risk of prostate cancer', Prostate, vol. 65, no. 1, pp. 44-51. https://doi.org/10.1002/pros.20259
Friedrichsen DM, Hawley S, Shu J, Humphrey M, Sabacan L, Iwasaki L et al. IGF-I and IGFBP-3 polymorphisms and risk of prostate cancer. Prostate. 2005 Sep 15;65(1):44-51. https://doi.org/10.1002/pros.20259
Friedrichsen, Danielle M. ; Hawley, Sarah ; Shu, Jainfen ; Humphrey, Mariela ; Sabacan, Leah ; Iwasaki, Lori ; Etzioni, Ruth ; Ostrander, Elaine A. ; Stanford, Janet L. / IGF-I and IGFBP-3 polymorphisms and risk of prostate cancer. In: Prostate. 2005 ; Vol. 65, No. 1. pp. 44-51.
@article{e97dbf624e9c474886d5b1ee2d51e8f0,
title = "IGF-I and IGFBP-3 polymorphisms and risk of prostate cancer",
abstract = "BACKGROUND. Insulin-like growth factor-I (IGF-I) is a potent mitogen for both normal and malignant prostate epithelial cells. The majority of circulating IGF-I is bound in a complex with IGF binding protein-3 (IGFBP-3), which in turn limits IGF-I bioavailability. Multiple studies suggest that higher IGF-I and/or lower IGFBP-3 serum levels are positively associated with prostate cancer risk. Several polymorphisms within the IGF-I and IGFBP-3 coding regions have been associated with increased serum protein levels. METHODS. To ascertain the potential relationship between serum levels and polymorphism, and prostate cancer risk, we investigated the role of two polymorphisms the IGF-I cytosine-adenosine (CA)-repeat and the IGFBP-3 Ala32Gly, and prostate cancer in a population-based, case-control, study of middle-aged men. RESULTS. We found no significant association between the IGFBP-3 Ala32Gly polymorphism and prostate cancer risk, even though the presence of at least one Gly allele did correlate with increased serum levels of IGFBP-3. For IGF-I, more controls (42{\%}) than cases (38{\%}) were homozygous for 19-CA-repeats (odds ratio, OR = 0.85; 95{\%} confidence interval (CI) = 0.66-1.09). After stratifying by disease characteristics, 19-CA-repeat homozygous men displayed a decreased risk of low-grade disease (OR = 0.50; 95{\%} CI = 0.27-0.93), but no associations were observed with more aggressive features of disease. Additionally, there was no correlation between mean serum IGF-I protein levels and IGF-I genotype in controls. CONCLUSIONS. Further evaluation of the IGF-I CA-repeat polymorphism and prostate cancer is necessary to determine if the modest risk reduction associated with the 19-CA-repeat homozygous state is observed in other study populations.",
keywords = "IGF-I, IGFBP-3, Polymorphisms, Prostate cancer, Relative risk",
author = "Friedrichsen, {Danielle M.} and Sarah Hawley and Jainfen Shu and Mariela Humphrey and Leah Sabacan and Lori Iwasaki and Ruth Etzioni and Ostrander, {Elaine A.} and Stanford, {Janet L.}",
year = "2005",
month = "9",
day = "15",
doi = "10.1002/pros.20259",
language = "English (US)",
volume = "65",
pages = "44--51",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - IGF-I and IGFBP-3 polymorphisms and risk of prostate cancer

AU - Friedrichsen, Danielle M.

AU - Hawley, Sarah

AU - Shu, Jainfen

AU - Humphrey, Mariela

AU - Sabacan, Leah

AU - Iwasaki, Lori

AU - Etzioni, Ruth

AU - Ostrander, Elaine A.

AU - Stanford, Janet L.

PY - 2005/9/15

Y1 - 2005/9/15

N2 - BACKGROUND. Insulin-like growth factor-I (IGF-I) is a potent mitogen for both normal and malignant prostate epithelial cells. The majority of circulating IGF-I is bound in a complex with IGF binding protein-3 (IGFBP-3), which in turn limits IGF-I bioavailability. Multiple studies suggest that higher IGF-I and/or lower IGFBP-3 serum levels are positively associated with prostate cancer risk. Several polymorphisms within the IGF-I and IGFBP-3 coding regions have been associated with increased serum protein levels. METHODS. To ascertain the potential relationship between serum levels and polymorphism, and prostate cancer risk, we investigated the role of two polymorphisms the IGF-I cytosine-adenosine (CA)-repeat and the IGFBP-3 Ala32Gly, and prostate cancer in a population-based, case-control, study of middle-aged men. RESULTS. We found no significant association between the IGFBP-3 Ala32Gly polymorphism and prostate cancer risk, even though the presence of at least one Gly allele did correlate with increased serum levels of IGFBP-3. For IGF-I, more controls (42%) than cases (38%) were homozygous for 19-CA-repeats (odds ratio, OR = 0.85; 95% confidence interval (CI) = 0.66-1.09). After stratifying by disease characteristics, 19-CA-repeat homozygous men displayed a decreased risk of low-grade disease (OR = 0.50; 95% CI = 0.27-0.93), but no associations were observed with more aggressive features of disease. Additionally, there was no correlation between mean serum IGF-I protein levels and IGF-I genotype in controls. CONCLUSIONS. Further evaluation of the IGF-I CA-repeat polymorphism and prostate cancer is necessary to determine if the modest risk reduction associated with the 19-CA-repeat homozygous state is observed in other study populations.

AB - BACKGROUND. Insulin-like growth factor-I (IGF-I) is a potent mitogen for both normal and malignant prostate epithelial cells. The majority of circulating IGF-I is bound in a complex with IGF binding protein-3 (IGFBP-3), which in turn limits IGF-I bioavailability. Multiple studies suggest that higher IGF-I and/or lower IGFBP-3 serum levels are positively associated with prostate cancer risk. Several polymorphisms within the IGF-I and IGFBP-3 coding regions have been associated with increased serum protein levels. METHODS. To ascertain the potential relationship between serum levels and polymorphism, and prostate cancer risk, we investigated the role of two polymorphisms the IGF-I cytosine-adenosine (CA)-repeat and the IGFBP-3 Ala32Gly, and prostate cancer in a population-based, case-control, study of middle-aged men. RESULTS. We found no significant association between the IGFBP-3 Ala32Gly polymorphism and prostate cancer risk, even though the presence of at least one Gly allele did correlate with increased serum levels of IGFBP-3. For IGF-I, more controls (42%) than cases (38%) were homozygous for 19-CA-repeats (odds ratio, OR = 0.85; 95% confidence interval (CI) = 0.66-1.09). After stratifying by disease characteristics, 19-CA-repeat homozygous men displayed a decreased risk of low-grade disease (OR = 0.50; 95% CI = 0.27-0.93), but no associations were observed with more aggressive features of disease. Additionally, there was no correlation between mean serum IGF-I protein levels and IGF-I genotype in controls. CONCLUSIONS. Further evaluation of the IGF-I CA-repeat polymorphism and prostate cancer is necessary to determine if the modest risk reduction associated with the 19-CA-repeat homozygous state is observed in other study populations.

KW - IGF-I

KW - IGFBP-3

KW - Polymorphisms

KW - Prostate cancer

KW - Relative risk

UR - http://www.scopus.com/inward/record.url?scp=24944531217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24944531217&partnerID=8YFLogxK

U2 - 10.1002/pros.20259

DO - 10.1002/pros.20259

M3 - Article

C2 - 15800934

AN - SCOPUS:24944531217

VL - 65

SP - 44

EP - 51

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 1

ER -